ArticleNature communications2024
Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Chondroitin sulfate shapes the unfolded protein response in osteosarcoma to sustain cancer cell survival during ER stress.Cell death & disease · 2026Article
- Distinct Proteomic and Glycosylation Signatures Differentiate A549 Tumor and BEAS-2B Nontumor Cell Line-Derived Small Extracellular Vesicles.Molecular & cellular proteomics : MCP · 2026Article
- Oncofetal chondroitin sulfate positive circulating tumor cells as prognostic biomarkers in early-stage melanoma.Scientific reports · 2026Article
- Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.Cell death & disease · 2026Article
- Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model.Frontiers in oncology · 2026Article
- TGF-β-induced epithelial to mesenchymal transition drives proteoglycan binding specificity of HPV-based drug conjugates for cancer cells.Frontiers in oncology · 2026Article
- Protein catenation potentiates antitumor activity of malaria VAR2CSA navigation CAR-T cells in a mouse model of hematological malignancies.Journal for immunotherapy of cancer · 2025Article
- Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer.bioRxiv : the preprint server for biology · 2025Article
- Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles.Journal of extracellular vesicles · 2025Article
- Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate.NPJ precision oncology · 2025Article
- Phage therapy as a revitalized weapon for treating clinical diseases.Microbiome research reports · 2025Review
- Mammalian cell-based production of glycans, glycopeptides and glycomodules.Nature communications · 2024Article
- Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors.EMBO molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Elena Ethel Vidal-CalvoCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. elena@sund.ku.dk.ORCID 0000-0001-9655-2106
Anne Martin-SalazarCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0009-0003-3831-8225
Swati ChoudharyCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Robert DagilCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-5594-0716
Sai Sundar Rajan RaghavanCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-2575-2685
Lara DuvnjakCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Mie Anemone NordmajCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Thomas Mandel ClausenVAR2 Pharmaceuticals ApS, Copenhagen, Denmark.
Ann SkafteCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0009-0006-1024-2224
Jan OberkoflerCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Kaituo WangDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-5922-7109
Mette Ø AgerbækCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-5865-2034
Caroline LøppkeCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0003-0679-5118
Amalie Mundt JørgensenCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-8554-7261
Daria RopacCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Joana MujollariCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Shona WillisCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Agnès Garcias LópezCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Rebecca Louise MillerCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8574-1948
Richard Torbjörn Gustav KarlssonCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0448-6135
Felix GoerdelerCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-7190-9145
Yen-Hsi ChenGlycoDisplay ApS, Copenhagen, Denmark.ORCID 0000-0001-9484-3145
Ana R ColaçoProteomics Research Infrastructure, University of Copenhagen, Copenhagen, Denmark.
Yong WangCollege of Life Sciences, Zhejiang University, Hangzhou, China.ORCID 0000-0001-9156-0377
Thomas LavstsenCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-3044-4249
Agnieszka MartowiczDepartment of Internal Medicine V, Haematology & Oncology, Comprehensive Cancer Center Innsbruck (CCCI) and Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.
Irina NelepcuVancouver Prostate Centre, Vancouver Coastal Health Research Institutes, Vancouver, BC, Canada.ORCID 0000-0002-9208-6934
Mona MarzbanVancouver Prostate Centre, Vancouver Coastal Health Research Institutes, Vancouver, BC, Canada.
Htoo Zarni OoVancouver Prostate Centre, Vancouver Coastal Health Research Institutes, Vancouver, BC, Canada.ORCID 0009-0009-8514-2713
Maj Sofie Ørum-MadsenVancouver Prostate Centre, Vancouver Coastal Health Research Institutes, Vancouver, BC, Canada.
Yuzhuo WangVancouver Prostate Centre, Vancouver Coastal Health Research Institutes, Vancouver, BC, Canada.ORCID 0000-0002-9749-8591
Morten A NielsenCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0003-2668-4992
Henrik ClausenCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0915-5055
Michael WiererProteomics Research Infrastructure, University of Copenhagen, Copenhagen, Denmark.
Dominik WolfDepartment of Internal Medicine V, Haematology & Oncology, Comprehensive Cancer Center Innsbruck (CCCI) and Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.
Ismail GögenurCenter for Surgical Science, Department of Surgery, Zealand University Hospital Køge, Køge, Denmark.
Thor G TheanderCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Nader Al-NakouziVAR2 Pharmaceuticals ApS, Copenhagen, Denmark.ORCID 0000-0002-4653-2884
Tobias GustavssonCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Mads DaugaardVAR2 Pharmaceuticals ApS, Copenhagen, Denmark. mads.daugaard@ubc.ca.ORCID 0000-0001-8383-055X
Ali SalantiCentre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. salanti@sund.ku.dk.ORCID 0000-0003-2207-5575
Funding
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MCarlsbergfondet (Carlsberg Foundation) CF20-0412Danmarks Grundforskningsfond (Danish National Research Foundation) DNRF107European Molecular Biology Organization (EMBO) ALTF 105-2063Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT-470421Innovationsfonden (Innovation Fund Denmark) 9065-00216ALundbeckfonden (Lundbeck Foundation) R324-2019-1855Lundbeckfonden (Lundbeck Foundation) R344-2020-934NCI NIH HHS P50 CA097186Novo Nordisk Fonden (Novo Nordisk Foundation) NNF19OC0058387Novo Nordisk Fonden (Novo Nordisk Foundation) NNF19SA0059305Novo Nordisk Fonden (Novo Nordisk Foundation) NNF22OC0073736
Abstract
Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express is oncofetal chondroitin sulfate (ofCS), which supports disease progression and dissemination in cancer. Here, we report the identification and characterization of phage display-derived antibody fragments recognizing two distinct ofCS epitopes. These antibody fragments show binding affinity to ofCS in the low nanomolar range across a broad selection of solid tumor types in vitro and in vivo with minimal binding to normal, inflamed, or benign tumor tissues. Anti-ofCS antibody drug conjugates and bispecific immune cell engagers based on these targeting moieties disrupt tumor progression in animal models of human and murine cancers. Thus, anti-ofCS antibody fragments hold promise for the development of broadly effective therapeutic and diagnostic applications targeting human malignancies.
Indexed as
Chondroitin SulfatesNeoplasmsAnimalsAntigens, NeoplasmCell Line, TumorEpitopesFemaleHumansImmunoconjugatesMicePeptide LibraryXenograft Model Antitumor AssaysAntigens, NeoplasmChondroitin SulfatesEpitopesImmunoconjugatesoncofetal antigensPeptide Library
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.